MedPath

ANI Pharmaceuticals Launches Estradiol Gel, 0.06% Following FDA Approval

  • ANI Pharmaceuticals has launched Estradiol Gel, 0.06%, after receiving final FDA approval for its Abbreviated New Drug Application, expanding its product portfolio.
  • The newly launched product is a generic version of EstroGel Gel, 0.06%, providing a more affordable alternative for patients requiring estradiol therapy.
  • According to IQVIA data, the U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7 million, indicating a substantial market opportunity for ANI Pharmaceuticals.
ANI Pharmaceuticals has announced the launch of Estradiol Gel, 0.06%, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). This development allows ANI Pharmaceuticals to introduce a generic version of EstroGel Gel, 0.06%, offering a cost-effective alternative for patients.
The launch of Estradiol Gel, 0.06% represents a significant step for ANI Pharmaceuticals in expanding its product offerings. According to August 2024 moving annual total (MAT) IQVIA data, the U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7 million, highlighting the market potential for this product.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Addyi: First Pill to Combat Low Libido in Women

The FDA has approved Addyi, marking the first pharmaceutical intervention for hypoactive sexual desire disorder (HSDD) in women.

Alembic Pharma Gains USFDA Approval for Generic Hypertension Drug Diltiazem Hydrochloride

Alembic Pharmaceuticals received USFDA approval for Diltiazem Hydrochloride Extended-Release capsules, a generic alternative to Bausch Health's Cardizem CD, used to treat hypertension.

Alembic Pharmaceuticals Receives USFDA Approval for Generic Hypertension Treatment

Alembic Pharmaceuticals has secured USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, used to treat hypertension.

Appili Therapeutics Gains FDA Alignment on ATI-1801 for Cutaneous Leishmaniasis

Appili Therapeutics announced FDA agreement on the development strategy for ATI-1801, a topical paromomycin formulation, streamlining its path to NDA submission.

FDA Approves Generic Estradiol Gel for Postmenopausal Symptom Relief

The FDA has approved a generic estradiol gel, 0.06% (ANI Therapeutics), for treating moderate to severe hot flashes and vaginal changes due to menopause.

ANI Pharmaceuticals Launches Generic Estradiol Gel Following FDA Approval

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

ANI Pharmaceuticals Launches Generic Estradiol Gel, 0.06% Following FDA Approval

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

ANI Pharmaceuticals Launches Generic Estradiol Gel, 0.06% Following FDA Approval

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

ANI Pharmaceuticals Launches Ketoconazole Shampoo, 2% Following FDA Approval

ANI Pharmaceuticals has received FDA approval and launched Ketoconazole Shampoo, 2%, a generic version of Nizoral®, marking another limited competition product.

Reference News

[1]
ANI Pharmaceuticals announces FDA approval of Estradiol Gel, 0.06% | Markets Insider
markets.businessinsider.com · Oct 25, 2024

ANI Pharmaceuticals launched Estradiol Gel, 0.06% after FDA approval, a generic version of EstroGel Gel, 0.06%, with U.S...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy